Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,963,102
-
Number of holders
-
217
-
Total 13F shares, excl. options
-
66,666,465
-
Shares change
-
+1,121,761
-
Total reported value, excl. options
-
$6,012,124,489
-
Value change
-
+$97,920,619
-
Put/Call ratio
-
139%
-
Number of buys
-
101
-
Number of sells
-
-118
-
Price
-
$90.19
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q3 2021
266 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q3 2021.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 217 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 66,666,465 shares
of 95,963,102 outstanding shares and own 69.47% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (11,459,046 shares), VANGUARD GROUP INC (5,874,831 shares), Capital International Investors (5,665,193 shares), FEDERATED HERMES, INC. (3,987,032 shares), BlackRock Inc. (3,450,553 shares), Capital Research Global Investors (3,361,792 shares), Capital World Investors (2,766,861 shares), WELLINGTON MANAGEMENT GROUP LLP (2,508,275 shares), Clearbridge Investments, LLC (2,365,621 shares), and ALKEON CAPITAL MANAGEMENT LLC (2,308,130 shares).
This table shows the top 217 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.